John M Hatcher

USPTO Granted Patents = 18 (Patent Applications = 13)

EPO Patents = 6 (Patent Applications = 24)

Average Co-Inventor Count = 3.9

ph-index = 1

Forward Citations = 4(Granted Patents)

Location History:

Marlborough, MA (US) (2019 - 2024)
Boston, MA (US) (2021 - 2024)

Company Filing History:

18 out of 1,206

Dana-farber-cancer Institute Inc.

Children's Medical Center Corporation

patents

where one patent can have more than one assignee

Years Active: 2019-2025

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12479847 - Pyrrolopyrimidine inhibitors of wild-type and mutant forms of LRRK2 (2025-11-25),

2. 12410194 - Potent and selective azaindole inhibitors of CDK8 and CDK19 (2025-09-09),

3. 12325725 - Cyclin-dependent kinase degraders and methods of use (2025-06-10),

4. 12275731 - Azaindole inhibitors of wild-type and mutant forms of LRRK2 (2025-04-14),

5. 12233128 - Degraders that target ALK and therapeutic uses thereof (2025-02-25),

6. 12157741 - Macrocyclic inhibitors of DYRK1A (2024-12-03),

7. 12157738 - Macrocyclic inhibitors of ALK, TRKA, TRKB, and ROS1 (2024-12-03),

8. 11945816 - Inhibitors of EGFR and/or HER2 and methods of use (2024-04-02),

9. 11858897 - Substituted 6,11-dihydro-5H-benzo[b]carbazoles as inhibitors of ALK and SRPK (2024-01-02),

10. 11542251 - IRAK degraders and uses thereof (2023-01-03),

11. 11248007 - Inhibitors of MALT1 and uses thereof (2022-02-15),

12. 11186574 - Inhibitors of EGFR and/or HER2 and methods of use (2021-11-30),

13. 11066363 - Substituted 6,11-dihydro-5H-benzo[B]carbazoles as inhibitors of ALK and SRPK (2021-07-20),

14. 10975055 - Inhibitors of interleukin-1 receptor-associated kinases and uses thereof (2021-04-13),

15. 10913744 - LRRK2 inhibitors and methods of making and using the same (2021-02-09),

Title: The Innovator John M Hatcher: Pioneering Advances in Cancer Treatment

Introduction:

John M Hatcher, a remarkable inventor based in Boston, MA, has been at the forefront of groundbreaking research and innovation in the field of oncology. With a total of 11 patents to his name, Hatcher's contributions have significantly impacted the development of targeted therapies for various types of cancer.

Latest Patents:

Hatcher's latest patents showcase his expertise in developing novel inhibitors for key molecular targets involved in cancer progression. One of his recent patents is for "Inhibitors of EGFR and/or HER2 and methods of use," which focuses on compounds that modulate the activity of HER2 and EGFR, essential proteins in cancer growth pathways. Additionally, his patent for "Substituted 6,11-dihydro-5H-benzo[b]carbazoles as inhibitors of ALK and SRPK" highlights his innovative approach towards targeting ALK and SRPK proteins in cancer treatment.

Career Highlights:

Throughout his career, John M Hatcher has made significant contributions while working with esteemed organizations such as the Dana-Farber Cancer Institute Inc. and Cornell University. His research and inventions have laid the foundation for developing effective therapies that target specific molecular pathways in cancer cells, leading to more personalized and precise treatment options for patients.

Collaborations:

Collaboration plays a crucial role in the field of research and innovation, and Hatcher has had the privilege of working alongside talented individuals such as Nathanael Schiander Gray and Pasi Antero Janne. Together, they have shared insights, expertise, and ideas, driving forward the advancement of cancer therapeutics and paving the way for future innovations in the field.

Conclusion:

In conclusion, John M Hatcher stands out as a visionary inventor who has dedicated his career to pioneering advances in cancer treatment. His patented inventions reflect his expertise in developing targeted therapies that hold great promise for improving outcomes in patients battling various forms of cancer. Hatcher's collaborative spirit and relentless pursuit of innovation continue to inspire progress in the fight against this complex disease.

This text is generated by artificial intelligence and may not be accurate.